Please ensure Javascript is enabled for purposes of website accessibility

This Is Why Teladoc Stock Rose Today

By Neil Rozenbaum – Oct 28, 2021 at 10:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A broken stock does not mean a broken company.

In this video, I will be going over Teladoc's (TDOC -5.33%)Q3 earnings report and trying to understand why the stock is down on a great print. You can find the video down below, but here are some of the highlights.

Earnings summary

The company reported earnings per share of -$0.53, beating estimates of -$0.65, and revenue of $522 million, up 81% year of year, beating estimates of $516.6 million. 

  • Total visits came in at 3.9 million, growing 37% year over year (YOY) and beating guidance by 10%. 
  • 70% of bookings were multiproduct sales, compared to 50% last year. 
  • Organic revenue grew 32% YOY, with domestic revenue up 89% YOY to $483 million and international revenue up 17% YOY to $39 million. 
  • Access fee revenue was $451 million, up 99% YOY, and visit fee revenue was $60 million, up 17.4% YOY. 
  • Per member per month (PMPM) was $2.57, up 117% YOY and 4.1% quarter over quarter. 
  • Gross profit margin (according to generally accepted accounting principles or GAAP) remained flat at 67.1%.

As for guidance for Q4 and FY21,

  • For Q4, the company expects revenue of $539 million and net loss per share of $0.69, beating expectations by 8.6% at the midpoint. 
  • For FY21, the company expects total revenue to be in the range of $2.015 billion to $2.025 billion. 
  • It expects visits to be between 14.5 million and 14.7 million, up 6% at the midpoint from previous guidance.  

The long-term thesis is still intact, and a broken stock does not equal a broken company

For the full insights, do watch the video below, and consider subscribing. 

*Stock prices used were the closing prices of Oct. 27, 2021. The video was published on Oct. 28, 2021.

Neil Rozenbaum has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy. Neil is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.